

4DMedical releases CT LVAS™ in Australia

25 October 2022

Highlights

- 4DMedical releases Computed Tomography Lung Ventilation Analysis Software (CT LVAS™).
- Expands patient accessibility by leveraging readily available CT hardware.
- Seamless integration enabled through the existing I-MED partnership.

Melbourne, Australia, 25 October 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, “4DMedical”, or the “Company”) today releases the latest addition to its product pipeline, CT LVAS™, in Australia.

4DMedical releases breakthrough ventilation software product CT LVAS™


4DMedical today announces the release of its breakthrough image processing software, CT LVAS™. CT LVAS™ provides an almost identical report to 4DMedical’s proven XV LVAS® product but utilises widely available Computed Tomography (CT) imaging infrastructure (instead of X-ray equipment), providing clinicians and patients with the benefits of XV Technology®.

Australia stands above the U.S., and every other nation outside of Japan, in terms of the density of CT scanners per head of population, making it the sensible launch point of this second product in the 4DMedical product pipeline. More importantly, it significantly broadens the accessibility of functional lung imaging for Australians living with lung disease.

Seamless integration of CT LVAS™ across the I-MED network

CT LVAS™ will position 4DMedical to leverage I-MED’s extensive existing CT network to provide greater patient access. CT LVAS™ uses existing CT hardware and has easy integration into clinical workflows across the I-MED network. In line with the Company’s commercialisation strategy, the I-MED agreement represents a significant opportunity to drive revenue for the Company, as it creates a framework for the rapid commercialisation of the CT LVAS™ product in Australia.

4DMedical’s product pipeline



The future of
lung health

Melbourne
Level 7
700 Swanston St,
Carlton, VIC, 3053
Tel: +61 (3) 9545 5940

Los Angeles
21255 Burbank Boulevard
Suite 102, Woodland Hills,
CA, 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



4DMedical CEO and Founder, Andreas Fouras, said:

“This product extension represents rapid progress in developing a more comprehensive product pipeline. CT LVAS™ also represents significant progress towards release of our CT:VQ technology, which will allow quantitative functional imaging of both ventilation (airflow) and perfusion (blood flow) within the lungs from a traditional CT scan. This advance will obviate the need for either CT contrast or nuclear imaging radiotracers, representing a material step forward for medical imaging and offering 4DMedical access to significant pricing premiums over XV LVAS® and CT LVAS™.”

–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Melanie Leydin

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS®), the first modality to dynamically quantify ventilation throughout the lungs.

XV LVAS® and CT LVAS™ reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.